English

SELLAS Life Sciences Group, Inc.

EDGAR

GALE Quarterly report (10-Q) · filed 2026-08-11

163 filing records in this dataset, filed from 2008-04-15 to 2026-08-11. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2023 Q4 · USD

Exact inputs and evidence

Revenue: 0 USD Source
Revenue: 0 USD Source

Operating cash flow

-4.83 million USD

2023 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -31410000 USD Source
Operating Cash Flow: -26585000 USD Source

Cash and cash equivalents: 138 million USD 2026-06-30 Source
Exact value

138300000 USD
Long-term debt including current maturities: 100 thousand USD 2018-09-30 Source
Exact value

100000 USD
Shares outstanding: 202 million shares 2026-06-30 Source
Exact value

201918874 shares

Reported share-count change

101.18% · 102 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

100367113 shares · 2025-06-30· Source
201918874 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

0 USD

2023-01-01 – 2023-12-31

Exact inputs and evidence

Revenue: 0 USD · 2023-01-01 – 2023-03-31 Source
Revenue: 0 USD · 2023-04-01 – 2023-06-30 Source
Revenue: 0 USD · 2023-07-01 – 2023-09-30 Source
Revenue: 0 USD · 2023-01-01 – 2023-12-31 Source
Revenue: 0 USD · 2023-01-01 – 2023-09-30 Source

Net income

-32.5 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -6791000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -26900000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -19200000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -8400000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -9605000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-28.4 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -23500000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -16400000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -28400000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -23500000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -8800000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -16400000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -8800000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

6 thousand USD

2016-01-01 – 2016-12-31

Exact inputs and evidence

Capital expenditure: 6000 USD · 2016-01-01 – 2016-03-31 Source
Capital expenditure: 6000 USD · 2016-01-01 – 2016-06-30 Source
Capital expenditure: 6000 USD · 2016-01-01 – 2016-03-31 Source
Capital expenditure: 6000 USD · 2016-01-01 – 2016-09-30 Source
Capital expenditure: 6000 USD · 2016-01-01 – 2016-06-30 Source
Capital expenditure: 6000 USD · 2016-01-01 – 2016-12-31 Source
Capital expenditure: 6000 USD · 2016-01-01 – 2016-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-11.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 5 of 11 periods available· newest 2023-12-31
Operating income: 10 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 2 of 11 periods available· newest 2016-12-31
Total assets: 11 of 11 periods available· newest 2025-12-31
Total liabilities: 11 of 11 periods available· newest 2025-12-31
Current assets: 11 of 11 periods available· newest 2025-12-31
Current liabilities: 11 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2025-12-31
Long-term debt including current maturities: 1 of 11 periods available· newest 2017-12-31
Shares outstanding: 11 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
+USD 3.98 million

Prior period

−USD 30.88 million

2024-01-01 – 2024-12-31
Current period

−USD 26.9 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-26900000 − -30881000 = 3981000 USD

-30881000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-26900000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · SELLAS Life Sciences Group, Inc. · 2025-12-31 SELLAS Life Sciences Group, Inc. (edgar:1390478) Year-over-year change in Net income: 3981000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:38:06Z Snapshot: 47301aa06ed9d7f1c2e461a02314a4242e1a4a66232bdf55be2b67f525a2a366 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1390478?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -26900000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1390478/000139047826000003/sls-20251231.htm#1339698 Filing: 000139047826000003 Input fundies:NetIncome: -30881000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1390478/000139047826000003/sls-20251231.htm#1282834 Filing: 000139047826000003
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 7 million

Prior period

−USD 35.4 million

2024-01-01 – 2024-12-31
Current period

−USD 28.4 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-28400000 − -35402000 = 7002000 USD

-35402000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-28400000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · SELLAS Life Sciences Group, Inc. · 2025-12-31 SELLAS Life Sciences Group, Inc. (edgar:1390478) Year-over-year change in Operating cash flow: 7002000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:38:06Z Snapshot: 47301aa06ed9d7f1c2e461a02314a4242e1a4a66232bdf55be2b67f525a2a366 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1390478?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -28400000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1390478/000139047826000003/sls-20251231.htm#1339858 Filing: 000139047826000003 Input fundies:OperatingCashFlow: -35402000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1390478/000139047826000003/sls-20251231.htm#1293634 Filing: 000139047826000003
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue, Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2023 2023-01-01 – 2023-12-31

Revenue USD 0
Operating costs Derived USD 37.87 million
Operating income −USD 37.87 million
Tax, interest and other Derived −USD 529,000
Net income −USD 37.34 million

Cash

Operating cash flow −USD 31.41 million
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2019 Not shown: operating income or net income is not reported.
2020 Operating loss: operating costs were 994% of revenue.
2021 Operating loss: operating costs were 433% of revenue.
2022 Operating loss: operating costs were 4,295% of revenue.
2023 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2019 2019-01-01 – 2019-12-31	0	20041000 Derived	-20041000	-749000 Derived	-19292000	Unavailable	Source 2019-01-01 – 2019-12-31: 0 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -20041000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -19292000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -17643000 USD Inspect Operating Cash Flow Open source
2020 2020-01-01 – 2020-12-31	1900000	18882000 Derived	-16982000	-225000 Derived	-16757000	Unavailable	Source 2020-01-01 – 2020-12-31: 1900000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -16982000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -16757000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -10417000 USD Inspect Operating Cash Flow Open source
2021 2021-01-01 – 2021-12-31	7600000	32894000 Derived	-25294000	-4595000 Derived	-20699000	Unavailable	Source 2021-01-01 – 2021-12-31: 7600000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -25294000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -20699000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -26021000 USD Inspect Operating Cash Flow Open source
2022 2022-01-01 – 2022-12-31	1000000	42950000 Derived	-41950000	-649000 Derived	-41301000	Unavailable	Source 2022-01-01 – 2022-12-31: 1000000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -41950000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -41301000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -23809000 USD Inspect Operating Cash Flow Open source
2023 2023-01-01 – 2023-12-31	0	37869000 Derived	-37869000	-529000 Derived	-37340000	Unavailable	Source 2023-01-01 – 2023-12-31: 0 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -37869000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -37340000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -31410000 USD Inspect Operating Cash Flow Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2023

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Revenue	0	Revenue: 0 Open source
20202020-12-31	Revenue	1900000	Revenue: 1900000 Open source
20212021-12-31	Revenue	7600000	Revenue: 7600000 Open source
20222022-12-31	Revenue	1000000	Revenue: 1000000 Open source
20232023-12-31	Revenue	0	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-100% 2023

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20202020-12-31	Year over year	No prior comparable period	Revenue: 1900000 Open source Revenue: 0 Open source
20212021-12-31	Year over year	300%	Revenue: 7600000 Open source Revenue: 1900000 Open source
20222022-12-31	Year over year	-86.8%	Revenue: 1000000 Open source Revenue: 7600000 Open source
20232023-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 1000000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -4,195% 2022

Net margin -4,130.1% 2022

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Operating margin	Not reported	Operating Income: -20041000 Open source Revenue: 0 Open source
20202020-12-31	Operating margin	-893.8%	Operating Income: -16982000 Open source Revenue: 1900000 Open source
20212021-12-31	Operating margin	-332.8%	Operating Income: -25294000 Open source Revenue: 7600000 Open source
20222022-12-31	Operating margin	-4,195%	Operating Income: -41950000 Open source Revenue: 1000000 Open source
20232023-12-31	Operating margin	Not reported	Operating Income: -37869000 Open source Revenue: 0 Open source
20192019-12-31	Net margin	Not reported	Net Income: -19292000 Open source Revenue: 0 Open source
20202020-12-31	Net margin	-881.9%	Net Income: -16757000 Open source Revenue: 1900000 Open source
20212021-12-31	Net margin	-272.4%	Net Income: -20699000 Open source Revenue: 7600000 Open source
20222022-12-31	Net margin	-4,130.1%	Net Income: -41301000 Open source Revenue: 1000000 Open source
20232023-12-31	Net margin	Not reported	Net Income: -37340000 Open source Revenue: 0 Open source
20192019-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -17643000 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 1900000 Open source Operating Cash Flow: -10417000 Open source
20212021-12-31	Free cash flow margin	Not reported	Revenue: 7600000 Open source Operating Cash Flow: -26021000 Open source
20222022-12-31	Free cash flow margin	Not reported	Revenue: 1000000 Open source Operating Cash Flow: -23809000 Open source
20232023-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -31410000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -31.4M 2023

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Operating cash flow	-17643000	Operating Cash Flow: -17643000 Open source
20202020-12-31	Operating cash flow	-10417000	Operating Cash Flow: -10417000 Open source
20212021-12-31	Operating cash flow	-26021000	Operating Cash Flow: -26021000 Open source
20222022-12-31	Operating cash flow	-23809000	Operating Cash Flow: -23809000 Open source
20232023-12-31	Operating cash flow	-31410000	Operating Cash Flow: -31410000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Free cash flow	Unavailable	Operating Cash Flow: -17643000 Open source
20202020-12-31	Free cash flow	Unavailable	Operating Cash Flow: -10417000 Open source
20212021-12-31	Free cash flow	Unavailable	Operating Cash Flow: -26021000 Open source
20222022-12-31	Free cash flow	Unavailable	Operating Cash Flow: -23809000 Open source
20232023-12-31	Free cash flow	Unavailable	Operating Cash Flow: -31410000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

228.3% 2023

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Liabilities / assets	63.3%	Total Liabilities: 10516000 Open source Total Assets: 16609000 Open source
20202020-12-31	Liabilities / assets	39.3%	Total Liabilities: 18088000 Open source Total Assets: 46049000 Open source
20212021-12-31	Liabilities / assets	22.6%	Total Liabilities: 5928000 Open source Total Assets: 26275000 Open source
20222022-12-31	Liabilities / assets	76.8%	Total Liabilities: 16092000 Open source Total Assets: 20943000 Open source
20232023-12-31	Liabilities / assets	228.3%	Total Liabilities: 14195000 Open source Total Assets: 6219000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.23× 2023

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Current assets / current liabilities	1.56×	Current Assets: 8242000 Open source Current Liabilities: 5290000 Open source
20202020-12-31	Current assets / current liabilities	2.99×	Current Assets: 36925000 Open source Current Liabilities: 12336000 Open source
20212021-12-31	Current assets / current liabilities	4.63×	Current Assets: 23044000 Open source Current Liabilities: 4982000 Open source
20222022-12-31	Current assets / current liabilities	1.14×	Current Assets: 17756000 Open source Current Liabilities: 15515000 Open source
20232023-12-31	Current assets / current liabilities	0.23×	Current Assets: 3172000 Open source Current Liabilities: 13735000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 17.68 million Exact value Exact value: -17681000 USD 2016-01-01 – 2016-12-31: -17681000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SELLAS Life Sciences Group, Inc. · 2016-12-31 SELLAS Life Sciences Group, Inc. (edgar:1390478) Net Income: -17681000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T16:38:06Z Snapshot: 47301aa06ed9d7f1c2e461a02314a4242e1a4a66232bdf55be2b67f525a2a366 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1390478/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -17681000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/sls-20171231.xml#982395 Filing: 000119312518117053 The citation records this snapshot. The page link may show a newer release later.	−USD 11.85 million Exact value Exact value: -11850000 USD 2016-01-01 – 2016-12-31: -11850000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SELLAS Life Sciences Group, Inc. · 2016-12-31 SELLAS Life Sciences Group, Inc. (edgar:1390478) Operating Cash Flow: -11850000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T16:38:06Z Snapshot: 47301aa06ed9d7f1c2e461a02314a4242e1a4a66232bdf55be2b67f525a2a366 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1390478/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -11850000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/sls-20171231.xml#982126 Filing: 000119312518117053 The citation records this snapshot. The page link may show a newer release later.	USD 6,000 Exact value Exact value: 6000 USD 2016-01-01 – 2016-12-31: 6000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SELLAS Life Sciences Group, Inc. · 2016-12-31 SELLAS Life Sciences Group, Inc. (edgar:1390478) Capital Expenditure: 6000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T16:38:06Z Snapshot: 47301aa06ed9d7f1c2e461a02314a4242e1a4a66232bdf55be2b67f525a2a366 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1390478/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1390478/000119312517291513/gale-20170630.xml#1467533 Filing: 000119312517291513 The citation records this snapshot. The page link may show a newer release later.	−USD 11.86 million Calculation and evidence -11850000 − 6000 USD Exact free cash flow: -11856000 USD 2016-01-01 – 2016-12-31: -11850000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 6000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SELLAS Life Sciences Group, Inc. · 2016-12-31 SELLAS Life Sciences Group, Inc. (edgar:1390478) Free cash flow: -11856000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T16:38:06Z Snapshot: 47301aa06ed9d7f1c2e461a02314a4242e1a4a66232bdf55be2b67f525a2a366 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1390478?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -11850000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/sls-20171231.xml#982126 Filing: 000119312518117053 Input fundies:CapitalExpenditure: 6000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1390478/000119312517291513/gale-20170630.xml#1467533 Filing: 000119312517291513 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 23.75 million Exact value Exact value: -23754000 USD 2017-01-01 – 2017-12-31: -23754000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SELLAS Life Sciences Group, Inc. · 2017-12-31 SELLAS Life Sciences Group, Inc. (edgar:1390478) Net Income: -23754000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T16:38:06Z Snapshot: 47301aa06ed9d7f1c2e461a02314a4242e1a4a66232bdf55be2b67f525a2a366 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1390478/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -23754000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1390478/000139047819000017/gale-20181231.xml#282726 Filing: 000139047819000017 The citation records this snapshot. The page link may show a newer release later.	−USD 10.99 million Exact value Exact value: -10989000 USD 2017-01-01 – 2017-12-31: -10989000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SELLAS Life Sciences Group, Inc. · 2017-12-31 SELLAS Life Sciences Group, Inc. (edgar:1390478) Operating Cash Flow: -10989000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T16:38:06Z Snapshot: 47301aa06ed9d7f1c2e461a02314a4242e1a4a66232bdf55be2b67f525a2a366 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1390478/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -10989000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1390478/000139047819000017/gale-20181231.xml#282302 Filing: 000139047819000017 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2018 2018-01-01 – 2018-12-31	−USD 27.67 million Exact value Exact value: -27670000 USD 2018-01-01 – 2018-12-31: -27670000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SELLAS Life Sciences Group, Inc. · 2018-12-31 SELLAS Life Sciences Group, Inc. (edgar:1390478) Net Income: -27670000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T16:38:06Z Snapshot: 47301aa06ed9d7f1c2e461a02314a4242e1a4a66232bdf55be2b67f525a2a366 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1390478/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -27670000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1390478/000139047820000007/gale-20191231.xml#287580 Filing: 000139047820000007 The citation records this snapshot. The page link may show a newer release later.	−USD 30.42 million Exact value Exact value: -30422000 USD 2018-01-01 – 2018-12-31: -30422000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SELLAS Life Sciences Group, Inc. · 2018-12-31 SELLAS Life Sciences Group, Inc. (edgar:1390478) Operating Cash Flow: -30422000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T16:38:06Z Snapshot: 47301aa06ed9d7f1c2e461a02314a4242e1a4a66232bdf55be2b67f525a2a366 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1390478/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -30422000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1390478/000139047820000007/gale-20191231.xml#287156 Filing: 000139047820000007 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2019 2019-01-01 – 2019-12-31	−USD 19.29 million Exact value Exact value: -19292000 USD 2019-01-01 – 2019-12-31: -19292000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SELLAS Life Sciences Group, Inc. · 2019-12-31 SELLAS Life Sciences Group, Inc. (edgar:1390478) Net Income: -19292000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T16:38:06Z Snapshot: 47301aa06ed9d7f1c2e461a02314a4242e1a4a66232bdf55be2b67f525a2a366 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1390478/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -19292000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1390478/000139047821000007/sls-20201231.htm#1223645 Filing: 000139047821000007 The citation records this snapshot. The page link may show a newer release later.	−USD 17.64 million Exact value Exact value: -17643000 USD 2019-01-01 – 2019-12-31: -17643000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SELLAS Life Sciences Group, Inc. · 2019-12-31 SELLAS Life Sciences Group, Inc. (edgar:1390478) Operating Cash Flow: -17643000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T16:38:06Z Snapshot: 47301aa06ed9d7f1c2e461a02314a4242e1a4a66232bdf55be2b67f525a2a366 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1390478/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -17643000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1390478/000139047821000007/sls-20201231.htm#1294690 Filing: 000139047821000007 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2020 2020-01-01 – 2020-12-31	−USD 16.76 million Exact value Exact value: -16757000 USD 2020-01-01 – 2020-12-31: -16757000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SELLAS Life Sciences Group, Inc. · 2020-12-31 SELLAS Life Sciences Group, Inc. (edgar:1390478) Net Income: -16757000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:38:06Z Snapshot: 47301aa06ed9d7f1c2e461a02314a4242e1a4a66232bdf55be2b67f525a2a366 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1390478/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -16757000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1390478/000139047822000006/sls-20211231.htm#1257839 Filing: 000139047822000006 The citation records this snapshot. The page link may show a newer release later.	−USD 10.42 million Exact value Exact value: -10417000 USD 2020-01-01 – 2020-12-31: -10417000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SELLAS Life Sciences Group, Inc. · 2020-12-31 SELLAS Life Sciences Group, Inc. (edgar:1390478) Operating Cash Flow: -10417000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:38:06Z Snapshot: 47301aa06ed9d7f1c2e461a02314a4242e1a4a66232bdf55be2b67f525a2a366 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1390478/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -10417000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1390478/000139047822000006/sls-20211231.htm#1286992 Filing: 000139047822000006 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2021 2021-01-01 – 2021-12-31	−USD 20.7 million Exact value Exact value: -20699000 USD 2021-01-01 – 2021-12-31: -20699000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SELLAS Life Sciences Group, Inc. · 2021-12-31 SELLAS Life Sciences Group, Inc. (edgar:1390478) Net Income: -20699000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:38:06Z Snapshot: 47301aa06ed9d7f1c2e461a02314a4242e1a4a66232bdf55be2b67f525a2a366 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1390478/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -20699000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1390478/000139047823000005/sls-20221231.htm#1212458 Filing: 000139047823000005 The citation records this snapshot. The page link may show a newer release later.	−USD 26.02 million Exact value Exact value: -26021000 USD 2021-01-01 – 2021-12-31: -26021000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SELLAS Life Sciences Group, Inc. · 2021-12-31 SELLAS Life Sciences Group, Inc. (edgar:1390478) Operating Cash Flow: -26021000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:38:06Z Snapshot: 47301aa06ed9d7f1c2e461a02314a4242e1a4a66232bdf55be2b67f525a2a366 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1390478/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -26021000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1390478/000139047823000005/sls-20221231.htm#1234398 Filing: 000139047823000005 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2022 2022-01-01 – 2022-12-31	−USD 41.3 million Exact value Exact value: -41301000 USD 2022-01-01 – 2022-12-31: -41301000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SELLAS Life Sciences Group, Inc. · 2022-12-31 SELLAS Life Sciences Group, Inc. (edgar:1390478) Net Income: -41301000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T16:38:06Z Snapshot: 47301aa06ed9d7f1c2e461a02314a4242e1a4a66232bdf55be2b67f525a2a366 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1390478/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -41301000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1390478/000139047824000004/sls-20231231.htm#1306533 Filing: 000139047824000004 The citation records this snapshot. The page link may show a newer release later.	−USD 23.81 million Exact value Exact value: -23809000 USD 2022-01-01 – 2022-12-31: -23809000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SELLAS Life Sciences Group, Inc. · 2022-12-31 SELLAS Life Sciences Group, Inc. (edgar:1390478) Operating Cash Flow: -23809000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T16:38:06Z Snapshot: 47301aa06ed9d7f1c2e461a02314a4242e1a4a66232bdf55be2b67f525a2a366 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1390478/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -23809000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1390478/000139047824000004/sls-20231231.htm#1321496 Filing: 000139047824000004 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2023 2023-01-01 – 2023-12-31	−USD 37.34 million Exact value Exact value: -37340000 USD 2023-01-01 – 2023-12-31: -37340000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SELLAS Life Sciences Group, Inc. · 2023-12-31 SELLAS Life Sciences Group, Inc. (edgar:1390478) Net Income: -37340000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T16:38:06Z Snapshot: 47301aa06ed9d7f1c2e461a02314a4242e1a4a66232bdf55be2b67f525a2a366 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1390478/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -37340000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1390478/000139047825000003/sls-20241231.htm#1317747 Filing: 000139047825000003 The citation records this snapshot. The page link may show a newer release later.	−USD 31.41 million Exact value Exact value: -31410000 USD 2023-01-01 – 2023-12-31: -31410000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SELLAS Life Sciences Group, Inc. · 2023-12-31 SELLAS Life Sciences Group, Inc. (edgar:1390478) Operating Cash Flow: -31410000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T16:38:06Z Snapshot: 47301aa06ed9d7f1c2e461a02314a4242e1a4a66232bdf55be2b67f525a2a366 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1390478/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -31410000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1390478/000139047825000003/sls-20241231.htm#1329882 Filing: 000139047825000003 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2024 2024-01-01 – 2024-12-31	−USD 30.88 million Exact value Exact value: -30881000 USD 2024-01-01 – 2024-12-31: -30881000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SELLAS Life Sciences Group, Inc. · 2024-12-31 SELLAS Life Sciences Group, Inc. (edgar:1390478) Net Income: -30881000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T16:38:06Z Snapshot: 47301aa06ed9d7f1c2e461a02314a4242e1a4a66232bdf55be2b67f525a2a366 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1390478/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -30881000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1390478/000139047826000003/sls-20251231.htm#1282834 Filing: 000139047826000003 The citation records this snapshot. The page link may show a newer release later.	−USD 35.4 million Exact value Exact value: -35402000 USD 2024-01-01 – 2024-12-31: -35402000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SELLAS Life Sciences Group, Inc. · 2024-12-31 SELLAS Life Sciences Group, Inc. (edgar:1390478) Operating Cash Flow: -35402000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T16:38:06Z Snapshot: 47301aa06ed9d7f1c2e461a02314a4242e1a4a66232bdf55be2b67f525a2a366 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1390478/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -35402000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1390478/000139047826000003/sls-20251231.htm#1293634 Filing: 000139047826000003 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2025 2025-01-01 – 2025-12-31	−USD 26.9 million Exact value Exact value: -26900000 USD 2025-01-01 – 2025-12-31: -26900000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SELLAS Life Sciences Group, Inc. · 2025-12-31 SELLAS Life Sciences Group, Inc. (edgar:1390478) Net Income: -26900000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:38:06Z Snapshot: 47301aa06ed9d7f1c2e461a02314a4242e1a4a66232bdf55be2b67f525a2a366 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1390478/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -26900000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1390478/000139047826000003/sls-20251231.htm#1339698 Filing: 000139047826000003 The citation records this snapshot. The page link may show a newer release later.	−USD 28.4 million Exact value Exact value: -28400000 USD 2025-01-01 – 2025-12-31: -28400000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SELLAS Life Sciences Group, Inc. · 2025-12-31 SELLAS Life Sciences Group, Inc. (edgar:1390478) Operating Cash Flow: -28400000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:38:06Z Snapshot: 47301aa06ed9d7f1c2e461a02314a4242e1a4a66232bdf55be2b67f525a2a366 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1390478/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -28400000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1390478/000139047826000003/sls-20251231.htm#1339858 Filing: 000139047826000003 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

163 filings · 3,802 latest values · 3,768 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001390478, 1390478, GALE, SLS, edgar:1390478

Also known as GALENA BIOPHARMA, INC., Galena Biopharma, Inc., RXI PHARMACEUTICALS CORP, SELLAS LIFE SCIENCES GROUP, INC., SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc.

Latest quarter

Revenue

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Company performance

What changed year over year

Net income

Operating cash flow

Where revenue goes

2023 2023-01-01 – 2023-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation